Profil
Roland Wandeler is President-Biopharma Business Unit at Grifols SA since 2024.
Former roles include Chief Executive Officer at Sundance Biosciences, Inc. from 2022 to 2023, VP, GM-US Bone Health & Cardiology Business Unit at Amgen, Inc., and Chief Operating Officer at MorphoSys AG from 2020 to 2021.
Education includes graduate and doctorate degrees from the Swiss Federal Institute of Technology.
Aktive Positionen von Roland Wandeler
| Unternehmen | Position | Beginn |
|---|---|---|
| GRIFOLS, S.A. | Corporate Officer/Principal | 01.01.2024 |
Ehemalige bekannte Positionen von Roland Wandeler
| Unternehmen | Position | Ende |
|---|---|---|
Encinal Bio, Inc. | Vorstandsvorsitzender | 01.10.2023 |
| MORPHOSYS AG | Geschäftsführer | 31.12.2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Roland Wandeler
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Grifols SA
Grifols SA Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceuticals, diagnostic and bio supplies | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Encinal Bio, Inc. |
















